Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in: Current Treatment Options in Oncology 6/2020

01-06-2020 | Ovarian Cancer | Gynecologic Cancers (LA Cantrell, Section Editor)

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Authors: Joanna Glajzer, LL.B, MD, Jacek P. Grabowski, MD, Jalid Sehouli, MD, Jacobus Pfisterer, MD

Published in: Current Treatment Options in Oncology | Issue 6/2020

Login to get access

Opinion statement

The choice of the right treatment regimen for recurrent ovarian cancer (rOC) remains a case-by-case decision. It is based on multiple factors that involve patient characteristics and biological factors at the same time. The prioritization of factors is still subject to changes with a trend towards a more personalized medicine. Therefore, participation and engagement in clinical studies constitutes a substantial need for the future development of the treatment algorithm of rOC.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.CrossRef
2.
Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441–53.CrossRef
3.
Group JALFARCFAG-MNCCSobotEGW. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;24(suppl_6):vi24–32.
4.
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.CrossRef
5.
Oskay-Ozcelik G, Alavi S, Richter R, Keller M, Chekerov R, Cecere SC, et al. Expression III: patients’ expectations and preferences regarding physician-patient relationship and clinical management-results of the international NOGGO/ENGOT-ov4-GCIG study in 1830 ovarian cancer patients from European countries. Ann Oncol. 2018;29(4):910–6.CrossRef
6.
Irena Rohr MK, Chekerov R, Oskay-Özcelik G, Richter R, Heinrich M, Taskiran C, et al. What are the expectations and preferences of patients with ovarian cancer to a maintenance therapy? A NOGGO/GCIG/ENGOT-ov22 survey (Expression IV) in 2101 patients. J Clin Oncol. 2017;35(15_suppl):e17096-e.CrossRef
7.
Hack TF, Pickles T, Ruether JD, Weir L, Bultz BD, Mackey J, et al. Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psycho-oncology. 2010;19(6):606–16.CrossRef
8.
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.CrossRef
9.
Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(2):289–95.CrossRef
10.
• Andreas Du Bois IV, Gwenael Ferron, Alexander Reuss, Werner Meier, Stefano Greggi, Pernille Tina Jensen, Frédéric Selle, Frederic Guyon, Christophe Pomel, Fabrice Lecuru, Rongyu Zang, , Elisabeth Avall-Lundqvist, Jae Weon Kim, Jordi Ponce, Francesco Raspagliesi, Sadaf Ghaem-Maghami, , Alexander Reinthaller, Philipp Harter, Jalid Sehouli. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35(15_suppl):5501. A randomized phase III study showing a PFS benefit of SSC in patients with first rOC only when CTR was achieved. OS data is not available yet.CrossRef
11.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–39.CrossRef
12.
•• Wilson MK, Pujade-Lauraine, E., Aoki, D., Mirza, M. R., Lorusso, D., Oza, A. M., du Bois, A., Vergote, I., Reuss, A., Bacon, M., Friedlander, M., Gallardo-Rincon, D., Joly, F., Chang, S. J., Ferrero, A. M., Edmondson, R. J., Wimberger, P., , Maenpaa, J., Gaffney, D., Zang, R., Okamoto, A., Stuart, G., Ochiai, K. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28(4):727–732. A consensus statement replacing the historical definition of platinum-free interval by therapy-free interval.CrossRef
13.
Grabowsk JP, Martinez-Villa C, Richter R, Taube ET, Braicu EI, Sehouli J. Association of Ki67 expression levels and therapy outcome in low-grade serous ovarian cancer. J Clin Oncol. 2019;37(15_suppl):5577.CrossRef
14.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet (London, England). 2003;361(9375):2099–106.CrossRef
15.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(29):4699–707.CrossRef
16.
Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, et al. A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study). Int J Clin Oncol. 2019.
17.
Grabowski JP, Sehouli J. Current management of ovarian cancer. Minerva Med. 2015;106:151–6.PubMed
18.
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(33):5165–71.CrossRef
19.
Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(9):1247–58.CrossRef
20.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.CrossRef
21.
Perren TJ, Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., , Kurzeder, C., du Bois, A., Sehouli, J., Kimmig, R., Stahle, A., Collinson, F., Essapen, S., Gourley, C., Lortholary, A., Selle, F., Mirza, M. R., Leminen, A., Plante, M., Stark, D., Qian, W., Parmar, M. K., Oza, A. M. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484–2496.CrossRef
22.
Oza AM, , Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A, Park-Simon, T. W., Rustin, G., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., Swart, A. M., Farrelly, L., Kaplan, R, Parmar, M. K., Perren, T. J. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–936.CrossRef
23.
24.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.CrossRef
25.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2039–45.CrossRef
26.
• APD JP, Baumann K, Rau J, Harter P, Joly F, Sehouli J, et al. Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer. Ann Oncol. 2018;29(Suppl 8):viii332–viii58 A randomized phase III study showing a significant improvement of PFS for treatment with CD-BEV compared to CG-BEV in patients with rOC suitable for platinum- based treatment.
27.
Pignata S, Lorusso D, Joly F, Gallo C, Colombo N, Sessa C, et al. Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17. J Clin Oncol. 2018;36(15_suppl):5506.CrossRef
28.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1302–8.CrossRef
29.
30.
31.
32.
33.
34.
35.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.CrossRef
36.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.CrossRef
37.
Grabowski JP, Sehouli J, Glajzer J, Worm M, Zuberbier T, Maurer M, et al. Olaparib desensitization in a patient with recurrent peritoneal cancer. N Engl J Med. 2018;379(22):2176–7.CrossRef
38.
• Pujade-Lauraine ELJ, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84 A double-blind, randomized, placebo-controlled, phase 3 trial showing a PFS benefit in patients with platinum- sensitive rOC and BRCAm when treated with olaparib.CrossRef
39.
Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018.
40.•
Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016(375):2154–64 A randomized, double-blind, phase 3 trial showing a PFS benefit in patients with platinum- sensitive rOC regardless of BRCA and HRD status when treated with niraparib.
41.
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019:Jco1802238.
42.
Moore KN, Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., Cristea, M., Berek, J. S., , Chan, J. K., Rimel, B. J., Matei, D. E., Li, Y., Sun, K., Luptakova, K., Matulonis, U. A., Monk, B. J. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636–648.CrossRef
43.
Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—results from ROC cohort. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018;36(suppl):106.CrossRef
44.
Penson RT, Drew Y, de Jonge MJA, Hong S, Park YH, Wolfer A, et al. MEDIOLA: a phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours–new ovarian cancer cohorts. Ann Oncol. 2018;29(suppl_8):viii133–viii14.
45.
Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR, et al. Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol. 2019;30(2):e18.CrossRef
46.
Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017;23(15):4095–106.CrossRef
47.
Swisher EMLK, Oza AM. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.CrossRef
48.
Konecny GE, Oza AM, Tinkerc AV, Colemand RL, O'Malleye DM, Maloneyf L, et al. Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: integrated summary of efficacy and safety from the phase II study ARIEL2. Gynecol Oncol. 2017;145(2):220.
49.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10106):1949–61.CrossRef
50.
LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–28.CrossRef
51.
Berek JS, Matulonis, U. A., Peen, U., Ghatage, P., Mahner, S., , Redondo, A., Lesoin, A., Colombo, N., Vergote, I., Rosengarten, O., Ledermann, J., Pineda, M., Ellard, S., Sehouli, J., Gonzalez-Martin, A., Berton-Rigaud, D., Madry, R., Reinthaller, A., Hazard, S., Guo, W., Mirza, M. R. Safety and dose modification for patients receiving niraparib. Ann Oncol 2018;29(8):1784–1792.CrossRef
Metadata
Title
Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Authors
Joanna Glajzer, LL.B, MD
Jacek P. Grabowski, MD
Jalid Sehouli, MD
Jacobus Pfisterer, MD
Publication date
01-06-2020
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 6/2020
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-020-00747-7

Other articles of this Issue 6/2020

Current Treatment Options in Oncology 6/2020 Go to the issue

Leukemia (PH Wiernik, Section Editor)

Biology and Treatment of Hairy Cell Leukemia

Lymphoma (DO Persky, Section Editor)

PI3K Inhibitors and Their Role as Novel Agents for Targeted Therapy in Lymphoma

Skin Cancer (T Ito, Section Editor)

Current Treatment of Melanoma Brain Metastasis

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms

Neuroendocrine Cancers (JR Strosberg, Section Editor)

Interventional Liver-Directed Therapy for Neuroendocrine Metastases: Current Status and Future Directions

Skin Cancer (T Ito, Section Editor)

The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits